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Abstract
Background: Chronic HIV infection results in the progressive depletion of CD4+ T
lymphocytes from both lymphoid tissues and peripheral blood. The existing studies tried
to address the evolution of CD4 cell count by using logistic and linear regression.
However, these models does not show the change of CD4 cell count over time rather
the effect of predictors on the evolution of CD4 cell count on the given point of time and
it gives biased inference for the estimates. This study designed to addresses this
problem by using longitudinal data analysis which accounts both fixed and random
effects on the model.
Objective: The aim of this study was to assess the CD4 count change over time and its
predictors among HIV positive children receiving antiretroviral therapy in Amhara region,
Ethiopia.
Methods: A retrospective follow up study was conducted among children who received
Antiretroviral Therapy between 2010 and 2016 in Amhara region public Hospitals.
Systematic random sampling was applied to select the 936 patients chart from the ART
registration book. The data were extracted from the selected chart by the trained data
collectors. The data were entered in to Epi info 7 and exported to stata14 for further
analysis. Since repeated measures were taken, correlation was taken in to account
when analyzing the data. Due to this illustration Linear Mixed Model was applied to
describe CD4 count change over time for children on ART.
Result: A total of 936 HIV positive patients were followed retrospectively with mean
CD4 count at baseline of 465.1cells/mm3 and an average rate of CD4 count change
5.01cells/mm3 per month. A patient having opportunistic infection (β = -0.048, 95% CI -
0.092, -0.0035), disclosed their status (β= -0.088, 95% CI -0.135, -0.041) and baseline
WHO clinical stage II (β = -0.0898, 95% CI -0.134, -0.046) are determinant predictors of
CD4 count change.
Conclusion: the average rate of CD4 count change over time was 5.01cells/mm3 per
month. The CD4 count change over time was described by quadratic time function. In
addition baseline WHO clinical stage, opportunistic infection, disclosure and regimen
type was significant predictors for CD4 count change.
Key words: CD4 count, Linear Mixed Model, Antiretroviral Therapy
11. Introduction
1.1 statement of the Problem
HIV/AIDS is one of destructive diseases human kind ever faced. It brings with it
profound social, economic, and public health consequences. It has become the world’s
most serious health and development challenges. HIV is a leading cause of death
worldwide. In addition Paediatric HIV has gone from being universally fatal to becoming
a treatable chronic condition[1, 2].
Among infants and children not taking ART, HIV infection is often rapidly progressive
and fatal. Approximately 20% of HIV-infected infants will die by 3 months of age without
treatment, half will die before reaching their second birthday, and three-fourths will die
by 5 years of age[3, 4]. Among those infected children 90% are found in sub Saharan
Africa[5].
According to Ethiopian public health institute ministry of health report on HIV related
estimate and projection in 2014 there are total of 95,795 infected children in Ethiopia in
2016 from this 48,411 are male and 47,384 are females. In addition from this year in
Ethiopia there are a total of 1,408 new infection of children and 1,459 annual related
deaths of children in this year[6].
Chronic HIV infection results in the progressive depletion of CD4+ T lymphocytes from
both lymphoid tissues and peripheral blood. Thus, the monitoring of peripheral blood
CD4 cell count is the standard used in decision-making concerning initiation of
antiretroviral therapy (ART), as well as monitoring response to ART over time[5, 7, 8].
The children with low CD4 count at pre-ART level initiated with HAART are more prone
to opportunistic infections, AIDS defining illness like malignancies, low BMI, decreasing
body weight, advanced clinical stage, poor phenotypic appearance, growth retardation
and lipoatrophy and dystrophy[9].
Combination of antiretroviral therapy (ART) is the only effective treatment available for
the suppression of HIV, and early ART initiation significantly reduces AIDS-related
initiation significantly reduces AIDS related morbidity and mortality among children[10].
2CD4 cell count and HIV RNA viral load in response to antiretroviral treatment are
important measures of the efficacy of ART in individual patients and the effectiveness of
ART in population of pediatric patients enrolled in HIV care and treatment programs[11].
Studies conducted on association between combination of ART and evolution of CD4
count on children [12-14]. However, the majorities of existing studies are based on small
number of participants and short duration of follow up as well as single centered study.
are does not show the  improvements of CD4 cell count over time it simply shows the
effect of predictors on the evolution of CD4 cell count on the given point of time because
simple regression and logistic regression models for repeated data are inadequate for
model fitting and can lead to inappropriate conclusions and inference.
In addition, there is limited information regarding the application of statistical models to
predict AIDS disease progression using longitudinal CD4 cell counts in Ethiopia.
The increasing number of HIV-infected children starting antiretroviral therapy and the
limited capacity to model CD4 cell count using longitudinal data analysis is the main
interest to indentify evolution of CD4 cell count in this study. The application of modeling
technique was essential due to repeated nature of data.
31.2 Literature review
1.2.1 Evolution of CD4 cell count
Study conducted in Bangalore and west Africa showed that early inception of HAART
mainly helps the children to maintain better CD4 count with good immune systems and
they are less prone to OI’s and it also reduces the progression of disease, mortality and
RNA plasma viral load[9, 15].
Study conducted in Zambia [16] on the objective of to report early clinical and
immunologic outcomes of children enrolled in the pediatric treatment program discuses
that children receiving ART showed significant improvement in CD4 cell count, weight
gain, and hemoglobin concentration.
Studies done on predicting patterns of long-term CD4 reconstitution in HIV-infected
children starting antiretroviral therapy in sub-Saharan Africa[17, 18] was briefly
discussed  that the majority of children (76%) had asymptotic CD4 reconstitution
following ART initiation, with an initial steep increase in CD4 cell count for age that
slowed with half life of 18 weeks tending towards a constant level over a long term of
(for a child of average demographics) , 80% of the CD4 count expected in an HIV-
uninfected child of the same age. CD4 for age both before ART and in the long term
were higher for children starting ART at younger ages, and long term CD4 reconstitution
was better in children with higher CD4 for age at ART initiation.
1.2.2. Determinants of CD4 count change
1.2.2.1. Socio demographic and clinical factors
study conducted on the objective to assess whether treatment of HIV infected children
with HAART would improve their immune function[13, 19] result showed that there is a
significant increase in the peripheral CD4 T-cell count at week 24 (median change, 231
cell/µl; range -33 to 548/µl [p=0.0029,wilcoxon signed rank test]) was accompanied by a
substantial decrease in the HIV load (median change, -1.64log10 copies/ml; range -2.98
to -0.12 log10 copies/ml [ p = 0.001]).
Study conducted on food insecurity and CD4% among HIV positive children in
Botswana[20] showed that food insecurity was inversely associated with CD4%,
4adjusting for covariates, among HIV positive pediatric patients in a sub-Saharan African
setting, the region with the highest prevalence of HIV in the world.
Studies conducted in Zimbabwe and Democratic republic of Congo[21, 22] showed that
the median CD4 cell count at different time points shows an increasing trend in the
levels of CD4 cell count with time for both age groups. From those age group and
baseline CD4 count were significantly associated with an increase in the levels of CD4
cell count over time.
A study conducted on Absolute CD4+ T-Lymphocyte Count as a Surrogate Marker of
Pediatric HIV Disease Progression[8] the result shows that there was a significant effect
of treatment regardless of the regimen on CD4+ T-lymphocyte counts (p <0.001) and
participants who had other infections or opportunistic infections had lower levels of
CD4+ T-lymphocyte counts.
A longitudinal single center observational study [23] supports that HAART induces a
beneficial effect in terms of clinical, virologic and immunologic outcomes even in
children previously exposed to antiretroviral therapy. They also found that CD4 T cell
increased significantly in most children (65%) irrespective of the extent of virologic
suppression and baseline age of children, baseline CD4 count and the number of ARVs
was found to predict immunological response.
A study conducted in India [24] discuses that non adherence children was associated
with loss of CD4 count and increase the viral suppression of immune system, while a an
adherent children was associated with CD4 gain, reduces drug resistance and viral load
suppression.
Studies conducted in Brazil on choosing the right strategy to model longitudinal count
data in epidemiology with application of CD4 cell counts [25] discuses that analysis of
longitudinal data using conventional regression models is inadequate as they fail to
consider the dependence between observations over time. Longitudinal data may also
present additional complexities in its structure, which may occur due to the imbalance
and/or the fact that they are unevenly spaced, or owing to missed data. It is up to the
date analyst to conduct a thorough exploratory analysis to evaluate the data structure
and choose the statistical model that best suits it.
5Figure 1: conceptual frame work of CD4 count change among HIV infected children receiving ART
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61.3 Justification
The CD4 cell count is a critical measure of immune system in HIV patients and is used
as an imperative biomarker for describing the progress to AIDS in children’s and adults.
Studies were conducted on the effects of ART on evolutions of CD4 cell count among
HIV positive children. However, the majorities of existing studies were without
considering the evolution of CD4 cell count over time and based on the assumption that
data are independent over time and this leads to the use of logistic and linear
regression model, but those models are inadequate for fitting correlated data and this
could leads to biased statistical inference. Hence, further study on the evolution of CD4
cell count using linear mixed models are needed for longitudinal data analysis. This
study is designed to examine the CD4 count change over time and to identify its
predictors among HIV positive children on ART in public Hospitals of Amhara region,
Ethiopia.
.
72. Objective
2.1 General objective
The aim of this study was to assess the CD4 count change over time and its predictors
among HIV positive children on antiretroviral therapy in Amhara region public Hospitals.
2.2 Specific objectives
 To examine the CD4 count change over time among HIV positive children on
Antiretroviral Therapy.
 To identify predictors which determine the CD4 count change among HIV
positive children on Antiretroviral Therapy.
83. Methods
3.1 Study area
The study was conducted in Amhara regional state public Hospitals. The region is found
in Northwest Ethiopia which is the second most populous with 19,602,512 estimated
total populations according to CSA 2011 report. The region have 19 public hospitals,
801 health center, 3302 health posts, and 1031 private health facilities (clinics and
hospitals). All the public health Hospitals provide ART service for both adults and
children of the people of Amhara and neighboring regions. According to regional health
office report over 2,112 pediatric patients are actively enrolled on ART in those hospitals
and clinics currently. From these about 70% of all ART services covered by the six
hospitals namely; Gondar university teaching and referral hospital, Debre markos,
Debre Birhan referral, Dessie, Debre tabor and Felegehiot specialized hospitals.
3.2 Study design
A retrospective follow up study was conducted during 2010- 2016 from ART clinic in
Amhara region.
3.3 Source population and study population
The source populations for this study were all HIV positive children from under the age
15 years that follow first line ART.
The study populations were all children that follow first line ART whose age is less than
15 years in Amhara region.
3.4 inclusion and exclusion criteria
3.4.1 Inclusion criteria:
All HIV positive children who started first line ART treatment and have at least two CD4
measurements were included in this study.
93.5 Sample size determination
The sample size for this study was done based on the following assumption
All subjects measured at m = 8 time points (no drop-out)
Constant within-subject correlation = 0.5
=1
We want 90% power to detect a difference d of 0.25 at the two-sided 0.05 significance
level.
=
( ( ) )( )
= ( ( ) . )( . . )( . ) = 467.86 ≈ 468
Therefore, the normal sample size calculation was give 468, but by adjusting design
effect 2 we get total sample of 936 subjects. Detailed sampling technique shown in the
next figure.
3.6 Sampling procedure
The sample of this study was performed on the selected major hospitals based on their
considerable coverage of patients served and independent probability sampling method
was conducted in order to select patients chart from patients’ registration book.
A proportional allocation was employed to those hospitals in order to obtain the best
precision of the outcome. Systematic random sampling technique was used to select
patient review chart from Gondar university teaching and referral, Felegehiot, Debre
markos, Debre Birhan, Dessie, and Debre tabor hospitals.
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Proportional allocation
Systematic random sampling
Figure 2: diagrammatic representation of sampling procedure
6 Hospitals in Amhara region
Felegehiot
n1 = 132
Debre tabor
n6 = 52
Debre markos
n2 = 239
Debre Birhan
n3 = 83
Dessie
n4 = 278
Gondar
n5 = 152
Total patients (n = 936)
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3.7 Study variables
3.7.1 Dependent variable
CD4 count
3.7.2 Independent variable
Explanatory variables are sex, age, baseline CD4 count, baseline weight, regimen type,
WHO staging, functional status, baseline hemoglobin level, disclosure, mothers ARV
status and time in months.
3.8 Operational definitions
Adherence: a child said to be adherent if she/he delayed from clinical attendance no
more than 3 days (visit more than 95% of appointment correctly) for each month. Good
adherence is >95%, fair adherence 85%-95% and poor Adherence <85% delayed from
clinical attendance (appointment) over the duration of the follow up.
3.9 Data collection instruments & procedures
The data collectors for this study were BSc Nurse working in the ART Clinic using
uniform data abstraction format prepared for this study.
3.10 Data quality assurance
The quality of data was ensured through training of data collectors and supervisors,
close supervision and prompt feedback. The training consisted of instruction on
extracting technique, a detailed review of the abstract form content with practical
demonstration.
The data was checked for any inconsistencies, coding error, out of range, completeness
accuracy, clarity and appropriate correction was made by principal investigator and
supervisors consistently on the daily basis.
3.11 Data processing & analysis
The data was entered in to Epi Info 7 and exported to stata14 for further analysis.
CD4 cell count at follow up time was described using the mean and standard deviation.
Frequencies were used to describe categorical variables like WHO clinical stage,
gender, opportunistic infection and primary care giver.
12
3.12 Statistical analysis
3.12.1 Exploratory data analysis
Exploration were done using graphical technique such as individual profile plot which
gives us an idea on the within and between subject variability and mean profile plot that
suggests the initial plausible assumption on the mean structure of model further more
variance function that will suggest initial assumption on the structure of random effects.
Average profile plots were constructed to describe the mean evolution of CD4 counts,
overall and according to different subgroups. From such exploration, indications were
obtained, about the functional form of the evolution and also whether the evolution
depends on given covariates. Smoothing using the Loess method was applied because
the measurements were not equally spaced across the different subjects. To get rid of
the skewness in CD4 data logarithmic transformation was applied and the analysis was
carried on with the transformed outcome.
To select the covariance structure which provides the best fit for the data and thus
reducing the risk of model misspecification, the four structures (identity, exchangeable,
independent and unstructured) was fitted and the one with the smallest model akaki
information (AIC) were selected. To determine the factors associated with changes in
CD4 cell count univariate analysis for each baseline factor was assessed and those
found to be significant (p-value<0.2) were selected in order to fit multivariable analysis.
3.12.2 Linear mixed models
Repeated measures of CD4 cell count were obtained every six months for 6 years in
HIV positive children on ART. The Linear Mixed Model is one of the statistical methods
used to analyze repeated measurements in continuous longitudinal data in an easy,
valid and flexible manner[26]. The linear mixed-effects model is defined as,
= + + Ԑ , ~ (0, ),Ԑ ~ (0,∑ )
Ԑ ,Ԑ ,… ,Ԑ
In which β is a vector of population-average regression coefficients called fixed effects,
and where bi is a vector of subject-specific regression coefficients? Describe how
the evolution of the subject deviates from the average evolution in the population.
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The matrices and are ×p and ×q matrices of known covariates. The
residual components Ԑi are assumed to be independent N (0;∑ ), where ∑ depends on i
only through its dimension
3.12.2.1 Univariate Linear Mixed Model
The main purpose of fitting univariate linear mixed model in this study was to select
important covariates used for fitting multivariate linear mixed model. The model
development process was carried out by selecting covariates that have the potential to
be included in the multivariate linear mixed model. Variable selection was done using
the manual backward selection criteria. It was carried out restricted maximum likelihood
method estimation and by using the selected correlation structure.
3.12.2.2 Multivariate Linear Mixed Model
In fitting the linear mixed model, a series of correlation structures of the longitudinal data
of CD4 counts on HIV patient were considered. From the possible covariance structures
in fitting the model, the one with the smallest AIC and convergence of the model in
REML and ML was considered. Restricted Maximum Likelihood (REML) was preferred
to Maximum Likelihood (ML) testing here, because it reduces the well-known finite down
ward bias in the estimation of the covariance. Those, unstructured correlation structured
was selected for assessing the change of CD4 counts by linear mixed model based on
the smallest AIC and BIC.
3.13 Model Diagnostics
In model diagnostics for longitudinal data analysis used for the residuals are frequently
used to evaluate the validity of the model assumption. In normal linear models residuals
are used to verify linearity of effects, normality, independence and homoscedasticity of
the errors and the presence of outliers or influent observations. The residual is the
difference between an observed quantity and its estimated or predicted value. Two
types of residuals were used in this study. Those are marginal residuals and the
conditional residuals .
The marginal residual are = − and the conditional residual = −
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4. ETHICAL CONSIDERATION
Ethical clearance was obtained from the University of Gondar College of Medicine and
Health science Institute of Public Health Ethical review committee. Letter of permission
to use the data were obtained from the authority of each hospital administration in HIV
care center. The study was conducted on secondary data so there is no harm to study
participants because there is no direct contact with the subjects and also patients’
identification numbers were used in the data set instead of names in order to keep their
confidentiality.
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5. Results
5.1 Sociodemographic, medication related, clinical and behavioral factors
Of the participants, 509 (53.4 %) were male and the primary caregiver for the children in
were predominantly the biological mother (parents) 731 (76.6%). In addition about
286(29.9%) patients were found in WHO stage I. 323(33.86%) of patients had working
functional status. 720(75.7%) were disclosed to the disease status while the rest
231(24.3%) were not. Furthermore, 691(72.8%) have other opportunistic infections (see
table1).
Table 1: Sociodemographic, medication related, clinical and behavioral characteristics ART data
set taken in Amhara region Hospital from 2010 –2016
Variable Category Frequency Percentage
Sex Male 509 53.5%
Female 442 46.5%
Primary care giver Parents 731 76.6%
Grand parents 93 9.8%
Relatives 68 7.2%
Others 58 6.1%
Regimen type d4T+3TC+NVP 327 34.3%
d4T+3TC+EFV 76 8.0%
AZT+3TC+NVP 333 34.9%
AZT+3TC+EFV 160 16.8%
Others 55 5.8%
Functional status Working 323 33.9%
Ambulatory 462 48.4%
Bedridden 166 17.5%
BWHO stage Stage I 286 29.9%
Stage II 309 32.4%
Stage III 287 30.1%
Stage IV 69 7.2%
Disclosure No 231 24.3%
Yes 720 75.7%
Opportunistic infection No 260 27.25%
Yes 691 72.8%
MARV status No 42 4.4%
Yes 909 95.5%
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The mean baseline age of children was 6.5 years with a standard deviation of 3.8 years;
the mean baseline CD4 count was 465.1cells/mm3 with a standard deviation of 398.3
cells /mm3; the mean weight at baseline for HIV positive children was 19.13kg with a
standard deviation of 9.5kgs, while the average baseline hemoglobin levels of children
at baseline were 12.4 mm/Hg with a standard deviation of 4.15 mm/Hg. finally the
average follow up time of children was 21.31months with a standard deviation of 18.75
months (see table2).
Table 2: Descriptive Statistics of Continuous Covariates at baseline for ART data
set taken in Amhara region from 2010-2016
BCD4 count BWeight Bhgb level BAge Time
Mean 465.1 19.13 12.4 6.5 21.31
Stand.dev 398.3 9.5 4.15 3.8 18.75
Where:
BCD4 count = baseline CD4 count
B Hgb level = baseline hemoglobin level
B Weight = baseline weight
B Age = baseline age
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5.2 Exploratory data analysis
5.2.1 Individual profile plot for some selected patients
The individual profile plot for a sample of 100 subjects was done. From the transformed
CD4 count, what can be noted from the panels is that generally there is evidence of
between subjects variability as well as within subject variability. The subjects have
largely variable CD4 values at the start and also possibly different evolutions over time;
this suggests that perhaps linear mixed models with random intercepts and slopes could
be plausible starting point. Also there is high within individual variability over time from
both females and males (see figure3 and figure4).
Figure 3: Individual profile plot for logCD4 count for ART data set taken from Amhara
region from 2010-2016
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Figure 4: Individual profile plots for logCD4 count grouped by gender for ART data set
taken from Amhara region from 2010-2016
5.2. 2. Exploring the mean structure
The transformed CD4 (logCD4) values were used throughout in the exploratory data
analysis. The data set was unbalanced in the sense that the number of repeated
observations per individual was not the same for all patients and the measurements for
all subjects were not taken at fixed time points of six monthly visits. The maximum
numbers of measurements per subject were 12.
The average CD4 count of children at baseline were 465.1cells/mm3 with a standard
deviation of 398.28 cells/mm3 , and it shows quick growth over time, further more the
average rate CD4 count change of children is 5.01cells/mm3 per month (see table3).
It is evident that the overall mean CD4+ count increases with time and stays stable over
time. The mean CD4 count increment for males and females over time are similar (see
figure5 and figure6).
The mean structure shown in (see appendix figure7), reveals that the average evolution
of CD4 by ART adherence logCD4 counts seems to have a fast growth around 24
months of after ART initiation and continued stable over a certain months.
time
(log)CD4 count
5
6
7
8
0 20 40 60 80
Female
0 20 40 60 80
Male
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Table 3: Mean, standard deviation, and Number subjects in each time for ART data set
taken from Amhara region from 2010-1016.
Time (month) Mean Std N
0 465.08 398.28 951
1 713.50 439.00 769
2 800.93 484.916 618
3 886.89 604.63 478
4 877.07 453 379
5 932.25 602.69 297
6 994.33 1195 232
7 905.00 588.72 159
8 874.45 391.50 107
9 868.52 399.98 60
10 952.83 427.16 41
11 953.18 436.51 22
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Figure 5: Smoothing Mean profile plots for the logCD4 count for ART data set taken from Amhara
region from 2010-2016.
Figure 6: Smoothing mean profile grouped by gender for ART data set taken from Amhara region
from 2010-2016
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5.2.3 Exploring correlation structure
The correlation matrix can be used to show the dependence between repeated
measurements of the responses over time.   The correlation matrix shown below
revealed a positive correlation between any two repeated measurements.
Pair wise scatter plots were used for exploring the correlation between any two
repeated measurements of CD4 count of patients and it appears that, there was a
positive and linear relationship between CD4 counts at different time points (see
figure7).
| CD40   CD41 CD42  CD43  CD44  CD45  CD46  CD47  CD48 CD49  CD410 CD411
CD40 |   1.0000
CD41 |   0.6554   1.0000
CD42 |   0.4640   0.7699   1.0000
CD43 |   0.6377   0.8529   0.8791   1.0000
CD44 |   0.6460   0.8725   0.5921   0.8795   1.0000
CD45 |   0.7175 0.9697   0.8229   0.9359   0.9139   1.0000
CD46 |   0.4778   0.8844   0.8489   0.9631   0.8898   0.9194   1.0000
CD47 |   0.0386   0.7113   0.5962   0.7044   0.7374   0.6769   0.8652   1.0000
CD48 | -0.2674   0.5237   0.5292   0.4794   0.4609   0.4784   0.6661   0.8969   1.0000
CD49 | -0.0981   0.6336   0.5822   0.5758   0.590   0.612   0.728   0.887 0.9718   1.0000
CD410 | -0.1389  0.6432  0.502  0.507   0.570   0.568   0.703   0.924   0.973   0.968 1.0000
CD411 | 0.0602 0.7492 0.7342 0.7021 0.6560 0.7349 0.8253 0.8928 0.9376 0.9775 0.9402 1.0000
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Figure 7: Scatter plot of correlation matrix for ART data set taken in Amhara region from 2010-
2016
5.2 Linear Mixed Model
5.2.1 Univariate Linear Mixed Models
Covariates selected by manually baseline hemoglobin level, baseline CD4 count, ART
adherence and gender is not significant effect on logCD4 count whose p-value > 0.2
from bivariate analysis, so we cannot enter in to multivariate analysis.
Table 4: selection of correlation structure for ART data set taken from Amhara region
from 2010-2016
Correlation structure AIC BIC
Identity 12987.52 13099.52
Independent 12898.62 13021.88
Exchangeable 12982.36 13083.17
Un structured 12854.43 12955.23
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Adding both random intercept and random slope are necessary to improve model fit
which accounts extra between variability (see table 5).
Table 5: Random Effects Models with the associated values for the likelihood ratio test and p-
value for ART data set taken from Amhara region from 2010-2016
Random effects Likelihood-ratio test p-value
Model1: intercepts 76.72 < 0.001
Model2: intercepts,  time 35.48 < 0.001
Quadratic time function best express our model (see table6)
Table 6: tests for model extension for ART data set taken from Amhara region from 2010-2016
Model REML log-likelihood
Linear 220.23
Quadratic 371.385
cubic -33.08
5.2.2 Multivariate Linear Mixed Model
The results of multivariate analysis shows that variables baseline height, height, weight,
and mothers ARV status were not significant predictor for the change in   logCD4 count
over time.
The average logCD4 count of children at baseline is 2.76 without consideration of
covariate effects. Time have significant factor on logCD4 count β1 = 0.0058 which
expresses that the average logCD4 count of an individual increased by 0.0058 per
month keeping the effect of other covariates constant.  Baseline WHO clinical stages
had undeniable effect on the logCD4 count change, that is, those patient who started
ART at late clinical stages showed lower evolution of CD4 counts compared to those
who started ART at earlier stages.
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In addition the negative coefficients for all WHO stages refers to at base line, their mean
CD4 counts are significantly lower than the reference group(i.e., p < 0.001 and < 0.001
for stage II,III respectively). However, over time all the three groups have significantly
better average CD4 count as compared to the reference group.
For example, time by WHO stage II interaction (β= 0.0076) with entails the rate of
increase in the logCD4 count for subjects in WHO stage II category is estimated to be
0.0076 times per month higher than the rate of increase among stage I patients.
Similarly, the rate of increase for subjects in stage III and IV categories are 0.0043 and
0.0059 times per month higher than the rate of increase in stage I patients respectively
or the rates of change in the average logCD4 counts are increased by 0.0043 and
0.0059 times per month among stage III and IV patients correspondingly.
Furthermore, at base line the mean logCD4 count among children who have other
opportunistic infection and disclosed to the disease and 0.088 times lower than the
mean logCD4 count among children who have not opportunistic infection and do not
disclosed to the disease (reference group) respectively.
Also age is strongly significant (p-value <0.001) risk factor for the change of logCD4
count which indicates that for every one year increase in age of children the average
logCD4 count is decreased by 0.018 times.
In addition regimen type have undeniable effect on the change of logCD4 count,
children take a combination of (d4T+3TC+EFV) drug lowers their logCD4 count by
0.098 times as compared to a children take (d4T+3TC+NVP) drug reference group
keeping the effect of other covariates constant, while children take a combination of
(AZT+3TC+EFV) drug gains logCD4 count by 0.02 times per month as compared the
reference group (d4T+3TC+NVP) keeping the effect of other covariates constant.
Also interaction effect of ART adherence with time also significant effect on the logCD4
count change, which means that patients who have fair ART adherence over time gains
an average logCD4 count 0.0059 times relative to poor ART adherence over time
keeping the effect of other covariates constant. In addition patients who have good
adherence over time gains an average logCD4 count 0.0057 per month relative to poor
ART adherence keeping the effect of other covariates constant (see table7).
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Table 7: multivariate analysis of linear mixed model for ART data set taken from Amhara region
from 2010-2016
Covariate Estimate p-value 95% CI
Constant 2.7579 0.000 2.580    2.936
Time .0058 0.000 .004   .0076
Time2 -.00018 0.000 -.000195 -.00016
WHO stage
Stage I 0
Stage II -.0898 0.000 -.13367 -.045894
Stage III -.1128 0.000 -.16048 -.06514
Stage IV -.0492 0.366 -.15603    .05754
Hemoglobin level .0102 0.018 .00175    .01864
Height -.000394 0.738 -.00270    .00191
Weight .00441 0.060 -.00019    .009008
Age -.0181 0.000 -.02698 -.00926
Opportunistic infection
No 0
Yes -.0476 0.034 -.09172 -.00354
Disclosure
No 0
Yes -.0878 0.000 -.13497 -.04057
Baseline Height -.0006895 0.600 -.00327    .00189
Baseline weight -.00284 0.186 -.00705    .00137
Regimen type
d4T+3TC+NVP 0
d4T+3TC+EFV -.09805 0.019 -.17969 -.01640
AZT+3TC+NVP .02044 0.435 -.0308   .0717
AZT+3TC+EFV .0713 0.030 .0069   .1356
TDF+3TC+EFV .1704 0.037 .01040 .3305
Others -.1056 0.567 -.4668     0.25567
WHO stage * time
Stage II*time .007590 0.000 .00587    .00930
Stage III*time .00434 0.000 .0028    .00589
Stage IV*time .00586 0.039 .000304    .0114
Regimen type*time
d4T+3TC+EFV*time .0015 0.0012 .0031    .00613
AZT+3TC+NVP* time -.0036 0.001 -.0056 -.0015
AZT+3TC+EFV* time -.0039 0.010 -.00689 -.00095
ART adherence
Fair*time .00597 0.004 .00500   .00693
Good*time .00546 0.0023 .0051 .00634
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The standard deviation of the intercept (boi= 0.276) this means that there is significant
variation of the intercepts between study subjects which implies that evolution of
logCD4 count vary across children at baseline.
It shows that the highest variability came from the random intercepts. It also shows that
the standard deviation of the random intercepts was higher than that of the random
slopes, pointing to higher between patient variability than the within patient variability.
The total variability between individuals is estimated as sd(bo)+ sd(b1) = 0.28 whereas
the total variability within individual is 0.163.
However, the total variation in CD4 count is estimated to be 0.163+0.28= 0.443. The
proportion of total variability that is attributed to within person variation is given by
0.163/0.443 is 36.7% while the proportion of total variability attributed to between
individual variations in their general level of CD4 count is  0.28/0.443 is 63.21%.
Therefore more than half of the variation is explained by the random intercepts and
random slops (see table 8).
Table 8: Random parameter estimates for ART data set collected in Amhara region from2010-2016.
Random intercept parameters Estimate Std error 95% CI
Sd(boi) 0.276 0.0076 .1892    .29812
sd(b1i) 0.004 0.00090 .00027 .00524
corr(b1i ,b0i) 0.729 0.2473 -.9611  .1070
sd(єij) 0.163 0027607 .1578     .1687
5.3 Model diagnostic checking
In model diagnostic checking for longitudinal data analysis we use residual plots in
order to evaluate the validity of model assumption. In normal linear model residuals are
used to verify linearization, normality, and homoscedasticity of the errors and presence
of outliers.
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Figure 8: residual plot for logCD4 count for ART data set taken from Amhara region from 2010-
2016
From this residual plot logCD4 count at each time point we understand that the
observations bellow and above the fitted line are similar this indicates that the data is
normally distributed with some sort of outliers.
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The histogram of the residuals with overlaid normal density estimator and the normal
quantile plot show that the residuals do not exhibit departure from normality. The
“Residual fit” concentrated around zero implies that linear mixed model were well fitted
the data.
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6. Discussion
The aim of this study was to assess the CD4 count change over time among HIV
positive children receiving antiretroviral therapy (ART) and its predictors. Since the data
is correlated Linear Mixed Model (LMM) were applied for statistical modeling.
The ART data was analyzed using different plots (exploratory analysis) followed by
model based outputs. From individuals profile plot, we observed the existence of
variability in CD4 count within and between individuals. The exploratory analysis result
for mean structure also suggested that on average, logCD4 tend to increase rapidly
following the initiation of antiretroviral therapy consistent with a study[17] which is a
reflection of the extent of suppression of viral replication, but it should be noted these
plots are mean plots which can possibly be different from individual plots this may show
some patients responding better than others.
The average rate change for CD4 count for this study was 30.04 six month or 60.08 per
year consistent with a study [8, 27] who founds that an adequate CD4 response for
most patients on therapy is defined as an increase in the range of 50–150 cells/mm3
per year with an accelerated response in the first 3 months of treatment
In addition the average logCD4 count increases in quadratic functions of time were
found to be appropriate descriptions of the CD4 count change. This supports the results
of [9, 28, 29] who found that after the patients initiated to the ART program their CD4
count increases and a dramatic decrease in viral load (VL) due to the therapy.
From multivariate linear mixed model we found covariates that have significant effect on
the CD4 count change those covariates are opportunistic infection, disclosure, regimen
type, WHO clinical stage, age, interaction effect of ART adherence, WHO clinical stage,
and regimen type with time and time while baseline height, sex, baseline hemoglobin
level, gender, mothers ARV status, have not significant effect on the change of CD4 cell
count over time.
There was a significant negative effect of other opportunistic infections (β = -0.048; 95%
CI -0.092, -0.0035), indicating that children who had other infections or opportunistic
infections had lower levels of CD4 cell counts this is consistent with a study[8, 18] but
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there was no significant difference between males and females in CD4 cell count
change at baseline this supports figure3 as well as a study[8, 18, 30].
Regimen types have significant effect on the change of logCD4 count i.e. patients
receiving two NRTI and one NNRTI shows low in logCD4 count gain at baseline this
result directly consistent with a study done long term effect of HAART on the evolution
of CD4 cell count among HIV positive children [11]. One of the possible reasons might
be known hematological toxicity of the drug and combination of other drug suppresses
CD4 count.
In addition disclosure has a negative effect on the change of CD4 cell count (β = -0.088,
with p-value < 0.001) this may be due to frustration of children from disease this leads to
stress and immunologic failure, but there is no studies related to association between
CD4 cell count and disclosure in children.
On the other hand WHO clinical stage has negative significant effect at baseline i.e.
Stage II and stage III but over time there is positive significant effect on the change of
CD4 count over time this contradicts study conducted in Zimbabwe [30] on comparison
of CD4 T-Cell changes in response to highly Active Antiviral Therapy (HAART) in
adolescents and children enrolled at Parirenyatwa Hospital Family Care Centre which
gets there is no significant effect on the change of CD4 cell count this may be due to
comparison of study between children and adolescent for their study while, our study is
studying the general trend of CD4 count change over time for all children, but this study
is consistent with a study conducted in Ghana[31] who founds that the negative
quadratic slope observed for children with more severe WHO clinical stages suggests a
significant slowing in the increase in CD4 absolute counts for that age group.
In this study adjusted multivariate analyses, age at ART initiation remained negatively
associated with logCD4 cell count (β = -0.018, 95% CI -0.027, -0.0093) this study is
consistent with a study conducted in West and sub Saharan Africa [15, 17, 32]. This
indicates that children at earlier age gains better CD4 recovery than older age. This
implies that understanding the impact of treatment initiation at different CD4 counts and
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age is essential to ensure that children reach adulthood with immune systems as
unbroken as possible.
Hemoglobin level also associated with the improvement of CD4 count over time
consistent with a previous study conducted in Gahanna[33] report shows that higher
level of hemoglobin associated with an increased CD4 counts, improved immune
reconstitution, and improved survival resulting in slower progression of disease; low
level of hemoglobin may be associated with AIDS and death in children live with HIV.
Good and fair adherence marker of timelines of clinic attendance over time positively
associated with the improvement of logCD4 count over time consistent with a study
conducted in Bangladesh and India[9, 24] the explanation of this might be effective
intake of ARV drug improves their CD4 count and enables to develop immunity and
reduce virologic suppression.
The limitation of the study is that the causal association between CD4 cell count, viral
load and other clinical parameters and over all treatment effect cannot be accurately
determined due to retrospective nature of data which does not record all the necessary
variables due to shortage of reagents or technical problems.
The strength of our study lies on the large number of children followed up along with
long duration of follow up to six years.
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7. Conclusion and recommendations
7.1 Conclusion
In conclusion the average rate of CD4 count change of children was originated on the
expected level. The CD4 cell count change over time could be sufficiently described by
a quadratic time function. The effects of several factors on the evolution were discussed
and the influences of several covariates on the evolution of logCD4 cell count were
indentified. Among these baseline WHO clinical stage, age, opportunistic infection,
regimen type, Hemoglobin level and disclosure was the determinant factors that
determine the CD4 count change in this study. In addition the interaction effect of ART
adherence, regimen type, and WHO clinical stages with time are determinant predictors
for CD4 count change over time.
7.2 Recommendations
The health care provider should made prompt management and diagnosis in order to
prevent increased risk of opportunistic infection. The health center should ascertain
counseling program to induce treatment adherence. Additional studies should conduct
including other essential covariates that were not included in this study.
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Annexes I
A. Data abstraction form of HIV Treatment related to children from 2010 to 2016
follow up in Amhara Regional Hospitals, Ethiopia
Part I – Baseline Characteristics
S.No
.
Characteristics /
variables
Records
101 Facility/Hospital
Name’s
____________
102 MRN No. ____________
103 Date of Birth ___/_____/____
104 Age at enrollment in
years (Month if <5
years)
_____________
105 Sex 1) Male 2)   Female
106 Child’s Address Region ________Zone __________Woreda__________ Kebele
__________
107 Primary care taker
relationship
1) Parents 2) Grandparents 3) Relatives(sister/brothers…) 4)
Orphanage 5) Others ___
108 Enrollment date
(DD/MM/YYYY)
_____/_____/______
109 HIV status Disclosure
to child’s
1) Yes 2)     No
110 Past OIs 1) Yes 2) No        if yes
specify____________________
111 Previous Child’s
mother ARV status
1) Yes 2)    No
112 If Q111 yes, which
ARV drug or ART
regimen
1) Sd-NVP 2) AZT 3)  Combination ARV 4) Other (specify)
_________
113 ART start date
(DD/MM/YYYY)
_____/_______/__________
114 First line ART regimen
code
1) 4a 2) 4b 3) 4c 4) 4d 5) 4e 6) 4f 7)
4g
115 Base line Height (cm) ____________
116 Base line Weight
(kg)
____________
117 Head circumference
(cm) if child < 5
_____________
37
years
118 Functional status of child 1) Working 2) Ambulatory 3) Bed ridden
119 Developmental status if
child < 5 years
1) Appropriate for age 2)   Delay 3) regression
120 WHO HIV clinical stages 1) I 2)     II 3) III 4) IV
121 Base line Hgb ___________________
PART II:   HIV care Follow up characteristics
201 202 203 204 205 20
6
207 208 209 210 211
No. Date Wei
ght
(kg)
Hei
ght/
HC
FS/
D.M
WH
O
stag
es
OI
s
CD4/mm3
or % if <5
Yrs
Hg
b
ARV drugs
Code Side
effects
Reason
for
change
if
Cou
nt
%
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
213 No. of visit based on Scheduled  ___________  No. of visit based Unscheduled____________  Total No. of visit _____________
No. of visit
Unscheduled
1 2 3 4 5 6 7 8 9 10 11 12
No.  of day
difference per visit
214 Last status of patients 1. Alive in first line 2. Died 3. Lost to follow up 4. Drop 5.Transfer to 6. Switch to second line
Data collector’s: Name _______________________    signature _________ date__________
Supervisor’s: Name _________________________signature ____________date __________
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Annexes II. Information Sheet and Consent Form
Information Sheet
Title of the research project: Predictors of the change of CD4+ cell counts among HIV
infected children receiving antiretroviral therapy (ART) in Amhara region, Ethiopia.
Retrospective longitudinal data analysis
Principal Investigator–Tilahun Yemanu (Bsc)
Advisors
1. Lemma Derseh (MPH, asst. professor)
2. Destaw Fetene (MPH)
Name of the organization: University of Gondar, College of Medicine and Health
Sciences, Institute of Public Heath, Department of Epidemiology and Biostatistics
Sponsor: University of Gondar
Introduction
My name is Tilahun Yemanu I am post graduate student at University of Gondar in
masters’ degree in Biostatistics; I am doing a research to determine the change in CD4
cell count and predictors that affect the change in CD4 count among HIV infected
children in Amhara region. A retrospective follow up study from HIV infected children in
Amhara region, north Ethiopia is my study area. This research includes one principal
investigator, ten data collectors, and three supervisors and two advisors from Gondar
University.
Purpose of the Research
The aim of this study is to describe the change of CD4 cell count over time and its
predictors among HIV infected children receiving antiretroviral therapy (ART) in Amhara
region, Ethiopia.
Confidentiality and Anonymity
The information that I collect for this research will be kept confidential. Information about
the patient that will be collected during the research will be stored in a file, which will not
write their name or rather I use personal identification number.
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Benefits: patients in this research project may not get direct benefit, but their benefit is
likely to help us to assess the change of CD4 cell count over time among HIV infected
children receiving antiretroviral therapy (ART) and factors that affect the change of CD4
cell count   In addition finally, it will give an insight for policy makers and programmers
to design new interventions.
Risks: in this study there is no risks occurred on the patient if we keep their
confidentiality.
Persons to contact
This research will be reviewed and approved by the Ethical Review board of University
of Gondar. If you wish to find about more or if you want to ask questions anytime you
can use the contact addresses below:
1. Tilahun Yemanu :University of Gondar
Tel: +251925978489                               E-mail: yemanu.tilahun@gmail.com
2. Lemma Derseh (MPH, assist. professor)
Tel: +251918773355
3. Destaw Fetene (MPH)
Tel: +251918037193
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Annexes III: Stata codes
############ convert data wide format in to long format##############
reshape long CD4 time WHO Weight Height Hgb FunctionalStatus Code Sideeffects
daydiferrence , i(UniqueKey) j(t)
======\\\\\\\=========
summarize CD4
/**mean profile plot with loess smoothing/****
lowess logCD4 time, mean
lowess logCD4 Weight, mean
lowess logCD4 time, mean lineopts(lcolor(cyan) lwidth(medthick) lpattern(solid) connect(direct))
by(, title("smoothing mean profile by treatment adherance")) by(TA_2)
lowess logCD4 time, mean recast(line) lineopts(lcolor(purple)) by(, legend(on)) by(WHO)
lowess logCD4 time, mean lineopts(lcolor(purple)) by(, title("smmothing by WHO clinical
stage")) by(, legend(on)) scheme(s2color) by(WHO)
lowess logCD4 time, mean lineopts(lcolor(purple)) by(, title("smmothing by ART regimen type"))
by(, legend(on)) scheme(s2color)
/***individual profile plot /*****
xtline CD4 if UniqueKey <=100, overlay t(time) tlabel(#6) i(UniqueKey) legend(off)
title("Individual Profiles") subtitle("n=100")
xtline CD4 if UniqueKey <=300, overlay t(time) tlabel(#6) i(UniqueKey) legend(off)
title("Individual Profiles") subtitle("n=300")
xtline logCD4 if UniqueKey <=300, overlay t(time) tlabel(#6) i(UniqueKey) legend(off)
title("Individual Profiles") subtitle("n=300"
xtline CD4 if WHOStage ==1 & UniqueKey <=250, overlay t(time) tlabel(#6) i(UniqueKey)
legend(off) title("IndividualProfiles for WHO clinical stage1") name(stage1, replace)
xtline CD4 if WHOStage==2& UniqueKey <= 200, overlay t(time) tlabel(#6) i(UniqueKey)
legend(off) title("Individual Profiles for WHO clinical stage2")  name(stage2, replace)
xtline CD4 if WHOStage==3& UniqueKey <= 200, overlay t(time) tlabel(#6) i(UniqueKey)
legend(off) title("Individual Profiles for WHO clinical stage3")  name(stage3, replace)
xtline CD4 if WHOStage==4& UniqueKey <= 1000, overlay t(time) tlabel(#6) i(UniqueKey)
legend(off) title("Individual Profiles for WHO clinical stage4")  name(stage4, replace)
xtline CD4 if FunctionalStatus ==1& UniqueKey <= 1000, overlay t(time) tlabel(#6) i(UniqueKey)
legend(off) title("Individual Profiles for FunctionalStatus")  name(bedriden, replace)
/*** linear mixed model /****
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xtmixed logCD4 time c.time#c.time c.time#c.time#c.time Weight Height i.FunctionalStatus i.OI
i.Primarycaretaker i.Disclosure i.MARVstatus BHeight Bweight i.WHOStage i.sex#c.time
i.Code#c.time  i.TA_2#c.time i.WHO#c.time i.OI#c.time i.Disclosure#c.time || UniqueKey:time
Height, cov(un) reml nolog
estat ic
### for multiple imputation####
mi set mlong
mi register imputed Weight
mi impute regress Weight, add(5) rseed(1234)
mi estimate: xtmixed logCD4 time Age i.sex Weight Height Hgb i.OI i.Disclosure i.MARVstatus ||
UniqueKey: time, cov(un) reml nolog
xtmixed logCD4 time Age Hgb i.OI#c.time i.Baselinecode i.Code#c.time i.Disclosure#c.time
i.MARVstatus i.TA_2#c.time i.WHO#c.time ||UniqueKey: time Age Hgb, cov(un) reml nolog
xtmixed logCD4 Age time i.OI i.Disclosure i.WHOStage i.WHO#c.time Hgb Height Weight
c.Height#c.time i.FunctionalStatus#c.time i.Baselinecode#c.time ||UniqueKey: time Hgb Age,
cov(un) reml nolog
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Annexes IV: some selected stata outputs
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Figure 9: Smoothing mean profile by ART adherence for ART data set taken from Amhara region
from 2010-2016
Table 6: univariate analysis for ART data set taken from Amhara region from 2010-2016
Covariates | Coef (Std. Err). z                    P>|z|                         [95% Conf. Interval]
cons | 2.703(.0115) 35.32 0.000                              2.680    2.7254
time |                .119(.005)                       24.45 0.000                       .1101806    .129384
(time)2 |                .0000488( 3.05e-6)        15.97 0.000                         .0000428    .0000548
sex(female) | -.0042(.0149) -0.28                  0.780 -.0334          .0251
Age | -.0289(.0018) -16.00                 0.000 -.0324892 -.0253983
Height | -.0027(.0003) -8.27                  0.000 -.0032855 -.0020263
BHeight | -.00068(.00019) -3.59                  0.000 -.0010589 -.0003112
Bweight | -.0079 (.00079) -10.02                0.000 -.009464 -.006368
Hgb | .00142(.0013)                 1.10                   0.272 -.0011111    .003940
BaselinHgb | -.00109(.0012) -0.93                  0.353 -.0033912    .001211
WHOStage (stage1 refe)
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1= poor adherence
2= fair adherence
3= good adherence
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stage2  | -.0492(.0188) -2.61                  0.009 -.0862 -.0123
stage3  | -.0415(.0191) -2.18                  0.030 -.0789 -.00414
stage4  |                  .0205 (.0309)                  0.66                   0.507 -.0401      .08114
Bregimentype |
2  | -.0975(.0274) -3.56 0.000 -.1511 -.04376
3  | -.0503(.017) -2.92                  0.004 -.0839 -.01650
4  | -.074(.0225) -3.29                   0.001 -.1178 -.0298
5  | -.0357(.0513) -0.70                  0.487 -.1361        .06485
6  |                        .180(.0726)                      2.48                    0.013                            .0378 .3224
OI (yes) | -.058(.0169 -3.43                   0.001 -.0913 -.02497
MARVstatus(yes) |       .1092(.0376)                     2.91                   0.004                            .0356 .1834
Disclosure(yes) | -.127(.0177) -7.21                  0.000 -.16195 -.0927
Primarycaretaker(parents refe)
GParents | -.0635(.0287) -2.22                0.027 -.1197 -.0074
Relatives | -.0311(.0342) -0.91               0.363 -.0983           .03599
Orphanage | -.1442(.0470) -3.07               0.002 -.2363 -.0520
FunctionalStatus(working refe)
Ambulatory |                 .0667(.0163)                 4.09                 0.000                              .0348 .09864
Bedridden | . 0147(.106)                 0.14                  0.890 -.1928            .2222
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